[Skip to Content]
[Skip to Content Landing]
Views 548
Citations 0
Comment & Response
April 2, 2020

Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer

Author Affiliations
  • 1The Medical Department, 3D Medicines Inc, Shanghai, China
  • 2State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
JAMA Oncol. Published online April 2, 2020. doi:10.1001/jamaoncol.2020.0283

To the Editor In a recent cohort biomarker study, Tie and colleagues1 demonstrated the prognostic value of circulating tumor DNA (ctDNA) analysis after either surgery or adjuvant chemotherapy in stage III colon cancer. We agree with and value the identification of longitudinal noninvasive markers of recurrence risk in patients with cancer; however, we would like to highlight additional aspects that should not be neglected in the study.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×